A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
暂无分享,去创建一个
Martin Augustin | Yinghong Gao | M. Augustin | Umesh A. Patel | S. Davies | Robert Kovelman | Stephen P Davies | Anna Woodward | Umesh A Patel | Kevin J Harvey | Yinghong Gao | K. Harvey | R. Kovelman | Anna M. Woodward
[1] J. Hamilton. CSF‐1 signal transduction , 1997, Journal of leukocyte biology.
[2] Y. Hashimoto,et al. Polyenylidene thiazolidinedione derivatives with retinoidal activities. , 1997, Chemical & pharmaceutical bulletin.
[3] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[4] J. Rubin,et al. Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a–dependent neurite outgrowth , 2011, The Journal of cell biology.
[5] R. Wenger,et al. Substrate preference and phosphatidylinositol monophosphate inhibition of the catalytic domain of the Per‐Arnt‐Sim domain kinase PASKIN , 2011, The FEBS journal.
[6] Gillian H. Little,et al. Critical Role of Nuclear Calcium/Calmodulin-dependent Protein Kinase IIδB in Cardiomyocyte Survival in Cardiomyopathy* , 2009, The Journal of Biological Chemistry.
[7] K. Kaibuchi,et al. Regulation and functions of Rho-associated kinase. , 2000, Experimental cell research.
[8] Y. Miki,et al. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. , 2012, The Journal of clinical investigation.
[9] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[10] J. Boehm,et al. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. , 1997, Bioorganic & medicinal chemistry.
[11] J. R. Daum,et al. Histone H3 Thr-3 Phosphorylation by Haspin Positions Aurora B at Centromeres in Mitosis , 2010, Science.
[12] Eric O Long,et al. β2 Integrin Induces TCRζ–Syk–Phospholipase C-γ Phosphorylation and Paxillin-Dependent Granule Polarization in Human NK Cells , 2011, The Journal of Immunology.
[13] Jung Kyoon Choi,et al. Identification of DNA methylation changes associated with human gastric cancer , 2011, BMC Medical Genomics.
[14] Philip R. Cohen,et al. PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.
[15] Pascal Furet,et al. Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. , 2006, Journal of medicinal chemistry.
[16] H. Gram,et al. Negative Regulation of Protein Translation by Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 , 2001, Molecular and Cellular Biology.
[17] K. Shokat,et al. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. , 2011, Annual review of biochemistry.
[18] J. Ham,et al. c-Jun and the transcriptional control of neuronal apoptosis. , 2000, Biochemical pharmacology.
[19] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[20] Y. Hashimoto,et al. Polyenylidine Thiazolidine Derivatives with Retinoidal Activities , 1997 .
[21] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[22] J. Rutter,et al. PAS Kinase Promotes Cell Survival and Growth Through Activation of Rho1 , 2012, Science Signaling.
[23] Jane Endicott,et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. , 2003, Journal of medicinal chemistry.
[24] S. Desiderio,et al. Mimicry of Pre–B Cell Receptor Signaling by Activation of the Tyrosine Kinase Blk , 2003, The Journal of experimental medicine.
[25] Jerry L. Adams,et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.
[26] M. Esteller,et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin , 2011, Oncogene.
[27] N. Walker,et al. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. , 2006, Bioorganic & medicinal chemistry letters.
[28] R. Wenger,et al. Substrate preference and phosphatidylinositol monophosphate inhibition of the catalytic domain of the PAS kinase PASKIN , 2011 .
[29] S. Nishikawa,et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.
[30] N. Gray,et al. In situ kinase profiling reveals functionally relevant properties of native kinases. , 2011, Chemistry & biology.
[31] S. Frye. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.
[32] J. Cox,et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts , 2009, Nature Methods.
[33] H. D. de Koning,et al. Pharmacological Validation of Trypanosoma brucei Phosphodiesterases as Novel Drug Targets , 2012, The Journal of infectious diseases.
[34] L. Galluzzi,et al. Selective killing of p53-deficient cancer cells by SP600125 , 2012, EMBO molecular medicine.
[35] F. Berger,et al. Inhibition of c-Jun N-terminal kinase by SP600125: a cDNA microarray analysis. , 2010, Cancer genomics & proteomics.
[36] David W. Anderson,et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[37] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[38] Mauro Riccaboni,et al. Spleen tyrosine kinases: biology, therapeutic targets and drugs. , 2010, Drug discovery today.
[39] K. Nishio,et al. Mitogen‐activated protein kinase phosphatase‐1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor‐tyrosine kinase , 2009, The FEBS journal.
[40] P. Cohen,et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.
[41] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[42] X. P. Liu,et al. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] J. Rutter,et al. PAS kinase: integrating nutrient sensing with nutrient partitioning. , 2012, Seminars in Cell and Developmental Biology.
[44] A. Kieser,et al. The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. , 2008, Virology.
[45] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[46] D. Payan,et al. Discovery and development of spleen tyrosine kinase (SYK) inhibitors. , 2012, Journal of medicinal chemistry.
[47] A. Itai,et al. Novel thiazolidinedione derivatives with retinoid synergistic activity. , 1998, Biological & pharmaceutical bulletin.
[48] P. Sorger,et al. Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.
[49] M. Hall,et al. Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.
[50] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[51] Stephen V Frye,et al. The art of the chemical probe. , 2010, Nature chemical biology.
[52] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[53] S. Bonner-Weir,et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and β-cell dysfunction , 2009, Proceedings of the National Academy of Sciences.
[54] S. Knapp,et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.
[55] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[56] Steven Finkbeiner,et al. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model , 2010, Proceedings of the National Academy of Sciences.
[57] P. Cohen,et al. The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.
[58] Joost C. M. Uitdehaag,et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets , 2012, British journal of pharmacology.
[59] Kevan M. Shokat,et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.
[60] S. Knapp,et al. The (un)targeted cancer kinome. , 2010, Nature chemical biology.
[61] Jens Timmer,et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. , 2009, Cancer research.
[62] S. Homma,et al. Inhibition of c-Jun-N-terminal Kinase Increases Cardiac Peroxisome Proliferator-activated Receptor α Expression and Fatty Acid Oxidation and Prevents Lipopolysaccharide-induced Heart Dysfunction* , 2011, The Journal of Biological Chemistry.
[63] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[64] P. Cohen. Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. , 2009, The Biochemical journal.
[65] N. Munshi,et al. JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* , 2003, The Journal of Biological Chemistry.
[66] Yanli Wang,et al. Identifying Compound-Target Associations by Combining Bioactivity Profile Similarity Search and Public Databases Mining , 2011, J. Chem. Inf. Model..